ALCAR Prophylaxis Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2008 by Royal Free Hampstead NHS Trust.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Bristol-Myers Squibb
Sigma-Tau Research, Inc.
Information provided by:
Royal Free Hampstead NHS Trust
ClinicalTrials.gov Identifier:
NCT00225160
First received: September 21, 2005
Last updated: September 17, 2008
Last verified: September 2008
  Purpose

The purpose of this study is to determine whether Acetyl L-carnitine can prevent the development of nerve damage, known as neuropathy, in individuals taking anti-HIV drugs over a 48-week period. In addition the safety and tolerability of Acetyl L-carnitine will be assessed.

This study compares the use of Acetyl L-carnitine or placebo (a dummy drug) in the prevention of nerve damage. The current standard of care is to use painkillers to manage the pain, with little or no effect. The possible beneficial effects of taking Acetyl L-carnitine is to prevent nerve damage as a result of anti-HIV medication.

The main purposes of the trial are:

  • to look at the differences in between those on Acetyl L-carnitine versus those on placebo
  • to look at the effect on state of your nervous system in the two treatment groups by measuring nerve activity
  • to learn more about the safety and tolerance of Acetyl L-carnitine

Condition Intervention Phase
HIV Infections
Distal Symmetric Polyneuropathy
Drug: acetyl L-carnitine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Randomised Double Blinded Placebo Controlled Pilot Study to Evaluate the Safety and Efficacy of Acetyl L Carnitine in Combination With Antiretroviral Therapy for the Prevention of Distal Symmetric Polyneuropathy and Lipid Abnormalities in Treatment naïve HIV Infected Subjects

Resource links provided by NLM:


Further study details as provided by Royal Free Hampstead NHS Trust:

Primary Outcome Measures:
  • The change from baseline in total area of Protein Gene Product (PGP) immunostaining on the epidermis at 48 weeks

Secondary Outcome Measures:
  • -Proportion of patients requiring analgesic agents
  • -Changes in the global assessments of pain by both subject and investigator
  • -Proportion of patients with HIV-1 RNA < 50 copies/ml at 24 and 48 weeks
  • -Proportion of patients with virological failure at 24 and 48 weeks
  • -Changes in CD4+ cell count from baseline after 24 and 48 weeks of treatment
  • -Time to discontinuation of the randomised treatment and reasons for this
  • -Incidence of adverse events
  • -Incidence of clinical disease progression
  • -Proportion of patients at Weeks 24 and 48 and incidence of virological and clinical failure or treatment-limiting adverse events
  • -Proportion of patients with changes in lipid profiles
  • -Change in body habitus as measured by lipodystrophy questionnaire
  • -Change in QOL at Weeks 24 and 48
  • -Changes in subcutaneous adipose tissue mtDNA

Estimated Enrollment: 50
Study Start Date: November 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, aged > 18 years of age
  • HIV-1 infected as documented by a licensed HIV-1 antibody ELISA
  • Women of childbearing potential must have a negative serum (beta-HCG; performed by a medical doctor - Austria only) pregnancy test within 28 days of starting study drug (and at monthly intervals for the duration for the trial (-Austria only)
  • Ability to assess level of pain and complete a pain log
  • Ability to understand and provide written informed consent to participation in this trial
  • All clinical laboratory values must be considered not clinically significant - for the potential response to the planned new regimen - in the opinion of the investigator
  • Naïve to antiretroviral therapy

Exclusion Criteria:

  • Diminished ankle reflexes (compared to the knee) or absent ankle reflexes. OR
  • Distal diminution of either vibration sense in the legs (defined as perception vibration < 10 seconds at the great toe with a tuning fork initially struck hard enough to be audible) or pain or temperature sensation.
  • Subjects who in the investigator's opinion are unlikely to complete the 48 weeks trial period.
  • Subjects with current alcohol or illicit drug use which, in the opinion of the investigator, may interfere with the subjects' ability to comply with the dosing schedule and protocol evaluations.
  • Previous treatment with any drug known to induce peripheral neuropathy, specifically excessive alcohol, isoniazid & vincristine.
  • Subjects with insulin dependent diabetes or cancer and an existing peripheral neuropathy or hereditary neuropathy.
  • Subjects with Vitamin B 12 deficiency (level < 150pg/mL)
  • Subjects using neurotoxic systemic therapeutic agents, systemic corticosteroids or immunomodulators within 30 days of randomisation.
  • Use of a medication for neuropathic pain during 2 weeks prior to randomisation (including tricyclic antidepressants, mexilitene, phenytoin or carbamazepine).
  • Subjects who have taken L-carnitine within 6 last months, or who have ever taken ALCAR.
  • Subjects being pregnant or breast feeding.
  • Subjects suffering from a serious medical condition, including one or more AIDS defining events (Appendix 8), which in the opinion of the investigator, would compromise the safety of the subject
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00225160

Locations
United Kingdom
Royal Free Hospital
London, United Kingdom, NW3 2QG
Sponsors and Collaborators
Royal Free Hampstead NHS Trust
Bristol-Myers Squibb
Sigma-Tau Research, Inc.
Investigators
Principal Investigator: Armin - Rieger, MD University of Vienna Medical School AKH
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00225160     History of Changes
Other Study ID Numbers: ALCAR
Study First Received: September 21, 2005
Last Updated: September 17, 2008
Health Authority: United Kingdom: Department of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Denmark: Danish Dataprotection Agency
Austria: Federal Ministry for Health and Women

Keywords provided by Royal Free Hampstead NHS Trust:
HIV
poly neuropathy
acetyl L-carnitine
treatment naïve
combination antiretroviral therapy
Lipid abnormalities

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Polyneuropathies
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Carnitine
Acetylcarnitine
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Nootropic Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 16, 2014